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OBJECTIVE: The aim of this study was to determine the cost-effectiveness of using baseline neuromoni-
toring (BNM) compared with multimodality monitoring (M3) for severe traumatic brain injury (TBI).
METHODS: Sixty-two patients with severe TBI underwent a prospective observational study where they
were divided into two groups of patients receiving treatment with M3 (32 patients) and BNM (30 patients).
The macro and micro costings were performed on each patient. The Barthel Index score after 1 year was
used as an outcome measurement tool for both groups. The cost-effectiveness (CE) ratio was calculated
using the Poisson regression model.
RESULTS: The costs of equipment and consumables between the groups was statistically significant
(p < 0.001) after correcting for age and severity of injury. Other cost categories were not significantly dif-
ferent. The crude CE ratios were 168.66 (95% CI: 168.32, 169.03) and 144.16 (95% CI: 143.87, 144.45) for
BNM and M3 respectively. The two crude CE ratios were significantly different (p < 0.001). It was calcu-
lated by controlling or adjusting age, gender, Glasgow Coma Score, Marshall’s classification at admission
and type of injury. The adjusted CE ratios were 171.32 (95% CI: 170.97, 171.68) and 141.50 (95% CI: 141.26,
141.79) for BNM and M3, respectively. The two adjusted CE ratios were significantly different (p < 0.001).
CONCLUSION: The application of M3 for severe TBI was more cost-effective than BNM. All calcula-
tions were made at 3.8 Malaysian Ringgit (MYR) to the United States dollar (USD). [Asian J Surg
2007;30(4):261–6]
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Introduction
The use of multimodality monitoring (M3) has improved
the mortality and morbidity of patients with severe trau-
matic brain injury (TBI).1 A few studies have shown a
definitive benefit of intensive monitoring in TBI,2–9 but
none of these studies looked into the cost-effectiveness of
M3. However, in Malaysia, a developing country in South
East Asia, scarcity of funds could affect the use of these
techniques and affect the funds used for M3 patients,
thus reducing cost-effectiveness in the long run. In our
hospital, all disposables for M3 and baseline neuromoni-
toring (BNM) are provided free as part of service. Even
though the usage of intracranial pressure (ICP) monitoring
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has grown to become a standard technique in the man-
agement of severe TBI in Malaysia, the use of other modali-
ties such as transcranial Doppler ultrasonography (TCD),
jugular venous oximetery (SjVO2), cerebral oxygen moni-
toring (TiBO2) and others has improved the outcome of
patients with TBI with expert personnel guiding the treat-
ment toward a better quality of life for these patients.10–13
However, these will either directly or indirectly increase
the total cost of management of such patients. During
this period, costs for medical and surgical supplies are
greatest for persons with severe brain injuries and those
who eventually spend the longest time in the neurointen-
sive care unit (neuro-ICU).14,15 Additionally, individuals
with more severe injuries receive the highest pharmacy
bills.16 Two techniques for neurotrauma monitoring in
patients with severe TBI in Hospital Universiti Sains
Malaysia (HUSM) have been used by two different neuro-
surgeons for the past 3 years. One surgeon believed that
the application of BNM, mainly focused on ICP monitor-
ing, was sufficient to achieve the best treatment outcome.
The other surgeon, who used M3 such as TCD, SjVO2 or
TiO2 on top of ICP monitoring, believed that using only
BNM was not adequate for detecting adverse brain condi-
tions that might result in a poorer medical outcome, lead-
ing to higher direct medical expenditure and indirect
costs. The objective of this study was to determine the
cost-effectiveness of using BNM compared with M3 in
neuromonitoring for severe TBI. This was done to help
the decision makers form a proper policy or adjust the
policy in the best interests of patient care particularly if
either M3 or BNM was not cost-effective.
Patients and methods
Study protocol
Ethical approval was given by the research and ethical
committee of Universiti Sains Malaysia (number USM/
304/PPSP/6131281) for a follow-up period of 6 months.
All the examinations and procedures were performed by
the respective teams. The cost of all the items and equip-
ment were calculated based on the type of care provided
to each patient. This was a prospective observational cost-
effectiveness analysis study conducted from January 2003
for a period of 1 year. In this study, the difference in the
total direct provider cost including the mean total equip-
ment cost, the difference in the mean outcome score and
the cost-effectiveness (CE) ratios between the provider
cost and outcome score were measured. All patients were
treated in the neuro-ICU of HUSM.
Description of the two study groups
The recruitment of patients for both groups started from
January 2003 till June 2003. During this period, all of the
patients underwent treatment in the hospital until they
were discharged. The micro and macro costing calcula-
tions were started from the day patients were admitted to
the neuro-ICU to the day of discharge. All severely head-
injured patients who met the following criteria were eligi-
ble to participate in this study: age 18–75 years; Glasgow
Coma Scale (GCS) score ≤ 8; brain injury that was trau-
matic in nature. In this study, the severity of the injury
not only relied on the GCS score but was based on the fea-
tures revealed on brain computed tomography (CT). All
brain CTs were interpreted according to the Marshall
Classification.17–19 Exclusion criteria included patients
who had a previous history of TBI or organic brain disease,
who had any chronic diseases such as diabetes, asthma or
hypertension or who had sustained any orthopaedic or
surgical injury.
The macro costing included the cost of the building,
equipment (assets worth more than US$132.00), salary,
operation and maintenance. The salary costs included
those of doctors and paramedics involved in taking care
of the patient during the neuromonitoring period in 
the neuro-ICU. The micro costing approach was used to
measure the costs of diagnostic imaging, laboratory tests,
drugs and consumables. All of the treatment costs were
measured by using budget information for the financial
year 2002. Only the direct provider costs were calculated
and the indirect costs and shared costs were presumed to
be equal in both groups because the study was conducted
at the same place and shared the same facilities. Follow-
up was conducted at 6 months post discharge. A patient’s
condition was assessed by using the Barthel Index scoring
system,20 which was chosen because of its comprehensive-
ness and because previous literature recommended it as 
a standard measure of physical disability in those with
neurological deficit.16 It consists of 10 series of physical
performance that need to be completed by patients.
The CE ratios of the two study groups were compared
using the Poisson regression model. Poisson regression
was used to compare rates (US$/Barthel Index improve-
ment) between the two study groups.21 The rates were
analysed as the dependent variable with the groups as the
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main independent variable with or without adjustment for
potential confounding variables (age, sex, GCS, Marshall’s
classification, type of injury). The crude and adjusted CE
ratio for each study group was obtained. Analyses were
performed using STATA version 7.0 (Stata Corp., College
Station, TX, USA).
Results
Characteristics of subjects
Sixty-two patients who sustained severe TBI were recruited
in this study. The characteristics of those who underwent
M3 were compared with those who underwent BNM.
These characteristics included age, sex, length of stay in
the neuro-ICU, type of injury, GCS and Marshall’s classi-
fication. None of these parameters were statistically sig-
nificantly different, indicating that the study groups were
comparable (Table 1).
Cost of M3 vs. BNM
Of the 62 patients involved, 32 were managed using M3
and 30 using BNM. In general, resource utilization in M3
subjects was higher compared with BNM subjects. Mean
total provider cost was US$8,023.78 and US$9,022.63 in
the BNM and M3 groups, respectively (Table 2). Salary
contributed most to the provider cost, where the mean
cost for managing patients was US$6,403.71 (70.97%) in
M3 patients and US$6,299.49 (78.51%) in BNM patients,
a non-significant difference (p = 0.93). Mean equipment
costs for patients undergoing M3 and BNM were US$474.92
and US$255.21, respectively (p < 0.001), and building costs
were US$37.23 and US$32.06, respectively (p = 0.22). Of all
the recurrent costs studied, only consumable costs showed
a significant difference, US$876.82 for M3 and US$321.25
for BNM, respectively (p < 0.001). The costs of operation
and maintenance, salary, drugs, imaging and laboratory
examinations were not significantly different between the
two groups.
Outcome measurement and CE ratio
The relationship between modality type and patient out-
come was based on the Barthel Index scoring system.
There was a statistically significant difference in the mean
Barthel Index score (p = 0.031) after 1 year of follow-up
(Table 3). This indicated that M3 produces a better out-
come compared with BNM, consistent with the finding
by Ruwaida et al.1 The crude CE ratios were 168.66 (95%
CI: 168.32, 169.03) and 144.16 (95% CI: 143.87, 144.45)
for BNM and M3, respectively. The two crude CE ratios
were significantly different (p < 0.001). Adjusted CE ratios
were calculated by controlling for age, gender, GCS and
Marshall’s classification at admission and by type of
injury. The adjusted CE ratios were 171.32 (95% CI:
170.97, 171.68) and 141.50 (95% CI: 141.26, 141.79) for
BNM and M3, respectively. The two adjusted CE ratios
were significantly different (p < 0.001) (Table 4).
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Table 1. Patient demographic and clinical characteristics
BNM M3 p
Age, yr (mean ± SD) 33.4 ± 18.86 34.2 ± 20.15 0.875*
GCS, median (IQR) 5.5 (2.0) 6.0 (2.0) 0.298†
Marshall classification, median (IQR) 3.0 (2.0) 3.0 (2.0) 0.795†
Length of stay, d (mean ± SD) 12.4 ± 6.13 14.4 ± 6.61 0.221*
Sex, n (%) 0.667‡
Male 27 (43.5) 30 (48.3)
Female 3 (4.8) 2 (3.2)
Type of injury, n (%) 0.105§
MVA 28 (45.2) 25 (40.3)
Fall 1 (1.6) 6 (9.7)
Fighting 1 (1.6) 1 (1.6)
*Independent t test; †Mann–Whitney test; ‡χ2 test; §Fisher’s exact test. BNM = baseline neuromonitoring; M3 = multimodality monitoring;
SD = standard deviation; IQR = interquartile range; MVA = motor vehicle accident.
Discussion
Global reports indicate that more than 20 million people
are severely injured or killed on the road each year.22,23
Most of them involve a motor vehicle accident (MVA).24
Similar results were found in this study where the leading
cause of severe head injury in both groups was MVA fol-
lowed by fall and other cause of injury (Table 1). The burden
is expected to fall most heavily on developing countries
like Malaysia because of the rapid increase in the number
of vehicles.24 In other reports, it was found that about two
thirds of those who were injured due to MVA involved
young adults.25,26 In this study, the mean age of the sub-
jects who sustained severe head injury in both groups was
33 and 34 years, respectively (Table 1). Murray and Lopez
emphasized the health problems, especially in terms of
potential years of lost life (PYLL), that arise from MVA-
related ill health and premature death, and reported that its
magnitude on PYLL was the second biggest in developing
countries, surpassed only by depression.26
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Table 2. Mean cost of neuromonitoring in Hospital Universiti Sains Malaysia, 2003*
Cost (US$)
p†
BNM (n = 30) M3 (n = 32)
Capital
Building 32.06 (15.81) 37.23 (17.04) 0.22
Equipment 255.21 (125.81) 474.92 (217.39) < 0.001
Recurrent
Operation & maintenance 29.45 (14.52) 34.19 (15.65) 0.22
Salary 6,299.48 (4,170.16) 6,403.71 (5,108.71) 0.93
Drug 427.92 (315.18) 451.75 (360.36) 0.78
Imaging 207.72 (19.04) 208.31 (22.89) 0.91
Laboratory 450.69 (370.81) 539.21 (571.78) 0.49
Consumables 321.25 (188.16) 876.82 (190.02) < 0.001
Total 8,023.78 (5,056.14) 9,022.63 (6,328.70) 0.49
*Data are presented as mean (standard deviation); †independent t test. BNM = baseline neuromonitoring; M3 = multimodality monitoring.
Table 3. Repeated measure ANOVA in the comparison of changes in the Barthel Index between the two study groups
Group/Time At admission, Mean (SD) At 6 mo, Mean (SD) F (df) p*
BNM 0.00 (0.0) 46.83 (30.36)
4.86 (1) 0.031
M3 0.00 (0.0) 63.75 (30.03)
*Null hypothesis: Barthel Index change is not different between the two study groups. BNM = baseline neuromonitoring; M3 = multimodal-
ity monitoring; SD = standard deviation; df = degrees of freedom.
Table 4. Comparison of crude cost-effectiveness ratio (CER) (US$/Barthel Index improvement) between the two study groups
Crude CER (95% CI) p* Adjusted CER† (95% CI) p*†
BNM 168.66 (168.32, 169.03)
< 0.001
171.32 (170.97, 171.68)
< 0.001
M3 144.16 (143.87, 144.45) 141.50 (141.26, 41.79)
*Poisson regression; †age, gender, Glasgow Coma Score and Marshall’s classification at admission and by type of injury were adjusted. With
or without adjustment for possible confounding variables, the CER of M3 was significantly lower than that of BNM (p < 0.001). CI = confi-
dence interval; BNM = baseline neuromonitoring; M3 = multimodality monitoring.
The financial impact of MVA is tremendous. Govern-
ments in developing countries need to spend a large
amount of money on the treatment and rehabilitation of
accident casualties. In Malaysia, health services provided
in the public sector are highly subsidized by the govern-
ment.25 The introduction of new health technologies like
the implementation of multimodality monitoring in severe
TBI increases health care costs.27
However, costing analysis by itself is not good enough
in guiding decision for options in health care. It only pro-
vides partial economic analysis. In developing countries
where the scarcity of resources is a major problem in the
provision of health care, cost analysis is regarded as a gen-
eral guide in allocating resources and acquiring technolo-
gies. The issue would not arise if the scarcity of resources
did not exist in a developing nation like Malaysia.
Currently, no published full economic analysis has been
performed comparing BNM and M3. Comparing BNM
and M3 definitely indicated that adding a set of new tech-
niques resulted in increased expenses in every cost category.
The costs of equipment and consumables, which were sig-
nificantly higher in M3, directly showed the cause of the
incremental cost since both groups were comparable in
terms of injury severity, injury type, age and sex (Tables 1
and 2). Adding new technologies for M3 resulted in more
capital investment in equipment and special consumables.
However, it did not result in significantly more man-hour
utilization as indicated by the lack of difference in salary
costs (p = 0.93). It also did not result in more drug, labo-
ratory facility and imaging services usage. The operation
and maintenance may not give a true result since M3
involves new modalities, so the equipment was still within
the life span and did not require any major technical
maintenance.
After 1 year follow-up, subjects who had undergone
M3 had a better outcome with a higher Barthel Index
score (p = 0.031). Both crude and adjusted CE ratios were
significantly different (p < 0.001). Improvement of a sin-
gle unit in the Barthel Index in M3 needed lesser mone-
tary implications compared with BNM. In other words,
the higher cost of M3 was compensated by a much greater
improvement in patient outcome (Table 3). Application
of M3 in neuromonitoring results in better real-time
monitoring of TBI patient progression during the acute
clinical period, leading to early detection of any deteri-
oration in brain function so that early remedial measures
can be initiated, thus preventing adverse effects on brain
function.13,28,29 In summary, M3 is much more cost-effective
than BNM in the neuromonitoring of the severe TBI patient.
The biggest limitations in this study were its sample
size and duration. For adequate statistical analysis, each
group should have at least 35 subjects. However, during
the study period, the current sample was the only sample
that could be achieved due to the strict enrollment criteria
that required written consent from the patients’ families.
A larger sample size and longer outcome measurement
would have resulted in less bias for outcome measurement.
Further, 6 months was the minimum interval required for
measuring the changes using the Barthel Index.14,15 Other
factors affecting the outcome of severe TBI patients that
were not measured in this study included good nursing
care at home, physiotherapy, and nutritional status.
Our results indicate that M3 is more cost-effective
than BNM. Improved access to M3 should be made avail-
able to severe TBI patients in dedicated centres in develop-
ing countries like Malaysia, especially where the population
is small, i.e. 26 million people, with a predominantly
young population. The successful recovery of these young
patients who may be rehabilitated after TBI in Malaysia is
warranted.
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